摘要
Background Pathological cardiac hypertrophy occurs in response to numerous stimuli and precedes heart failure (HF). Therapies that ameliorate pathological cardiac hypertrophy are highly needed. Methods The expression level of miR-30d was analyzed in hypertrophy models and serum of patients with chronic heart failure by qRT-PCR. Gain and loss-of-function experiments of miR-30d were performed in vitro. miR-30d gain of function were performed in vivo. Bioinformatics, western blot, luciferase assay, qRT-PCR, and immunofluorescence were performed to examine the molecular mechanisms of miR-30d. Findings miR-30d was decreased in both murine and neonatal rat cardiomyocytes (NRCMs) models of hypertrophy. miR-30d overexpression ameliorated phenylephrine (PE) and angiotensin II (Ang II) induced hypertrophy in NRCMs, whereas the opposite phenotype was observed when miR-30d was downregulated. Consistently, the miR-30d transgenic rat was found to protect against isoproterenol (ISO)-induced pathological hypertrophy. Mechanistically, methyltransferase EZH2 could promote H3K27me3 methylation in the promotor region of miR-30d and suppress its expression during the pathological cardiac hypertrophy. miR-30d prevented pathological cardiac hypertrophy via negatively regulating its target genes MAP4K4 and GRP78 and inhibiting pro-hypertrophic nuclear factor of activated T cells (NFAT). Adeno-associated virus (AAV) serotype 9 mediated-miR-30d overexpression exhibited beneficial effects in murine hypertrophic model. Notably, miR-30d was reduced in serum of patients with chronic heart failure and miR-30d overexpression could significantly ameliorate pathological hyper-trophy in human embryonic stem cell-derived cardiomyocytes. Interpretation Overexpression of miR-30d may be a potential approach to treat pathological cardiac hypertrophy.
学科与关键词
- Diverging targets mediate the pathological role of miR-199a-5p and miR-199a-3p by promoting cardiac hypertrophy and fibrosisZeng, Ni; Huang, Yu-Qing; Yan, Yu-Min; Hu, Zhi-Qin; Zhang, Zhuo; Feng, Jia-Xin; Guo, Ji-Shen; Zhu, Jie-Ning; Fu, Yong-Heng; Wang, Xi-Pei; Zhang, Meng-Zhen; Duan, Jin-Zhu; Zheng, Xi-Long; Xu, Jin-Dong*; Shan, Zhi-Xin*Molecular Therapy-Nucleic Acids, 2021, 26: 1035-1050.被引 15
- FTZ protects against cardiac hypertrophy and oxidative injury via microRNA-214 / SIRT3 signaling pathwayZhang, Yue; Sun, Mengxian; Wang, Dongwei; Hu, Yaju; Wang, Ruonan; Diao, Hongtao; Shao, Xiaoqi; Li, Yun; Li, Xu; Leng, Mingyang; Wang, Lexun; Yan, Meiling; Rong, Xianglu; Guo, Jiao*Biomedicine and Pharmacotherapy, 2022, 148: 112696.被引 5
- MicroRNA-24-3p alleviates cardiac fibrosis by suppressing cardiac fibroblasts mitophagy via downregulating PHB2Zhang, Yue; Wang, Zhiying; Lan, Dingming; Zhao, Jingjing; Wang, Lexun; Shao, Xiaoqi; Wang, Dongwei; Wu, Kaili; Sun, Mengxian; Huang, Xueying; Yan, Meiling; Liang, Haihai; Rong, Xianglu; Diao, Hongtao*; Guo, Jiao*Pharmacological Research, 2022, 177: 106124.被引 13
